Overview

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Status:
Not yet recruiting

Trial end date:
2025-10-22

Target enrollment:

Participant gender:

Summary

This trial is a phase I/II study, which is designed to evaluate the safety, tolerance, pharmacokinetic characteristics, receptor occupancy (RO), immunogenicity and effectiveness of LBL-019 monotherapy or combined with anti-PD-1 antibody in patients with advanced malignant tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Nanjing Leads Biolabs Co.,Ltd

Treatments:

Antibodies
Immunoglobulins